Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

about

From bench to bedside: bipolar androgen therapy in a pilot clinical study.

P2860

Q42120157-C644FE1D-FD49-4674-93DF-43852AE6876C

P2860

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

Item

http://www.wikidata.org/entity/Q42139770

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

@en

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

@nl

type

Item

label

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

@en

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

@nl

prefLabel

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

@en

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

@nl

P1476

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

@en

P2093

Anup Sharma

http://www.w3.org/2001/XMLSchema#string

Janet Mendonca

http://www.w3.org/2001/XMLSchema#string

Sushant Kachhap

http://www.w3.org/2001/XMLSchema#string

P2860

The mutational landscape of prostate cancer

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

A proteolytic pathway that recognizes ubiquitin as a degradation signal.

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

The mutational landscape of lethal castration-resistant prostate cancer

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.

Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes

Punctuated evolution of prostate cancer genomes.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

P304

435-436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/1008-682X.143750

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270001462

http://www.w3.org/2001/XMLSchema#string

P698

25532579

http://www.w3.org/2001/XMLSchema#string

P921

transcriptome

P932

4430943

http://www.w3.org/2001/XMLSchema#string

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

about

P2860

P2860

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932